A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia (SAPPHIRE)

In by ECIR

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia (SAPPHIRE)

  • This field is for validation purposes and should be left unchanged.
clinicaltrials.gov

Eligibility

Inclusion Criteria

– Male or female adult ≥18 years of age
– Should receive background standard of care treatment for albuminuria and/or Type 2 Diabetes
– Therapy should be optimized and stable and include an ACEi (Benazepril (Lotensin), Captopril (Capoten), Enalapril (Vasotec), Lisinopril (Prinivil, Zestril), Ramipril (Altace), Quinapril (Accupril)) or an ARB (Losartan (Cozaar), Candesartan (Atacand), Olmesartan (Benicar), Valsarta (Diovan), Irbestartan (Avapro)), unless contraindicated, or not tolerated
– eGFR ≥ 25
– UACR ratio between 30 – 5000 mg/g

Exclusion Criteria

– Carrier of the Human Leukocyte Antigen-B *58:01 allele
– Tumor lysis syndrome or Lesch-Nyhan syndrome
– Diagnosed with heart failure Class IV
– diagnosed with long QT syndrome
– Receiving cytotoxic or immunosuppressive therapy or other immunotherapy for primary or secondary renal disease

Back to Current Studies